Is Platelet Activity Important in Acute Intracerebral Hemorrhage?

Other potentially important factors that warrant further study include increased serum glucose, increased serum creatinine, low serum cholesterol, and elevated blood pressure [7, 8]. [12] studied 1,691 ICH patients from a prospective registry in Germany and found that pre-hospital antiplatelet use was associated with poor outcome in univariate analysis, however, it was not an independent predictor of ICH outcome after adjustment for age and pre-hospital status. Data from three well-designed prospective clinical studies suggest that if there is a biological association between prior antiplatelet use and ICH volume growth, it is modest at best. In an exploratory analysis of the phase II trial of recombinant activated factor VII (rFVIIa) in patients with ICH, which included five models of change in hemorrhage volume, prior use of antiplatelet agents was associated with ICH expansion in only one of the five models, whereas treatment with rFVIIa and a longer time from onset to baseline CT were related to a decrease in ICH expansion in all models [7]. [...]the current available data do not support an important effect of prior antiplatelet use on hematoma growth.